Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
He also worked on The Journal’s publishing desk; as a writer and editor covering stocks at Barron’s; as an editor of features at MarketWatch; and on product development efforts at The Journal.  ...
Insider Monkey on MSN11d
Why Moderna Inc. (MRNA) Crashed Last Week
In this article, we are going to take a look at where Moderna Inc. (NASDAQ ... saying that data on mRNA vaccines sent by the ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook
Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...
Advances in vaccine technology and the road ahead
Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
AOL8d
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
Kennedy Jr., a vocal vaccine skeptic ... HHS said its award to Moderna was, in part, to “enhance mRNA platform capabilities.” “The award made today is part of the ASPR’s commitment ...
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...